Robert Mulroy

Chief Executive Officer

Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.

Sarah Kurz

President and Chief Operating Officer

Sarah serves as President and Chief Operating Officer of PTx and chair of the company’s Executive Committee.  She has more than 20 years of experience building and leading successful private and public biopharma companies with expertise in oncology and rare disease. She previously served as PTx’s Executive Vice President and prior to that as the company’s Chief Commercial Officer. Sarah built her career with leadership responsibility across the product lifecycle continuum at Merrimack Pharmaceuticals, Ipsen Biopharmaceuticals, MacroGenics, and The Johns Hopkins University School of Medicine. She holds an undergraduate degree from Bowdoin College and an MBA and MPH from Emory University.

John McManus

President, Health Security

John serves as PTx’s President, Health Security. He has 25 years of leadership experience in the biopharmaceutical industry, that includes leading the transformation of several biotech companies through strategic partnerships and execution of value based strategies. John has been involved in health security and development of medical countermeasures for chemical, biological and radiological-nuclear threats for over 15 years during which time he has obtained and managed more than $500 million in procurement and development contracts. Prior to joining PTx, John was the CEO of Aeolus Pharmaceuticals where he focused on health security and respiratory, and served in strategic and financial roles at Spectrum Pharmaceuticals where he focused on oncology and NeoTherapeutics where he focused on Alzheimer’s, Parkinson’s, ALS and spinal cord injury. John holds a B.S. in International Finance and Business Economics from the University of Southern California

Debasish Roychowdhury, MD

Chief Technology Officer

Debasish serves as a director and the Chief Technology Officer of PTx. Debasish is a medical oncologist and a proven leader in the pharmaceutical industry with over 15 years of industry senior management experience and 14 years of patient care, academic research and teaching experience. Prior to PTx, he served as the Chief Medical Officer of Seragon through the company’s acquisition by Roche. Prior to Seragon, Debasish served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. Debasish is a member of the Board of Directors for Radius Health, Celyad, Lytix Biopharma AS and Fund+.

John Mulroy

Senior Vice President, Finance

As Vice President of Finance, John leads PTx’s finance and reporting capabilities. As a founding member of the PTx team, John built and implemented PTx’s core financial systems and business infrastructure. John also contributes significantly to financing initiatives and business development activities. John has a proven track record of solving complex business issues throughout the organization and is focused on ensuring PTx remains innovative, agile, and positioned for future growth. Prior to PTx, John served as Head of Business Operations at Silver Creek Pharmaceuticals where he served in similar roles establishing the business infrastructure and launching the company. John earned both his MBA and undergraduate degrees from Bentley University.

James “Jamie” Young

Vice President Manufacturing & Supply Chain

Jamie serves as the head of manufacturing and supply chain for PTx. He has 30 years of biologic manufacturing experience.  While at PTx, the scope of his responsibilities has broadened from API manufacturing, to API and DP manufacturing, to his current role.  Prior to PTx, he held management positions in Project Management, Technical Services, and Manufacturing under Sanofi, Genzyme, Bayer, and Berlex. Jamie started his career with Immunex and holds a BS in biology from Washington State University.

Lisa Rutter

Vice President, Quality

Lisa Rutter is the Vice President of Quality at Partner Therapeutics. She held the position of Executive Director & Head of Quality at Partner Therapeutics since 2017 until entering her current role in 2023.  Lisa previously held positions with Sanofi as Associate Director of Quality Control and Quality Systems Manager. She managed and was responsible for testing related to the manufacturing and release of Leukine, testing and release of raw materials, microbiological control of the utility systems and the manufacturing environment, program/system management of Deviation/CAPA, Change Control, Training and Document Management.

Prior to Sanofi, Lisa worked for Dendreon, Genentech, Amgen, and a contract research organization where she performed analytical method development, managed product testing laboratories conducting analytical release and stability testing of biological products and the implementation and administration of quality systems.

Lisa has a Bachelor’s Degree in Biology from Washington State University and brings 30 years of experience in biopharmaceuticals, including testing of clinical and commercial products and the development and management of Quality Systems with a focus on operational efficiencies using six sigma techniques and tools.